1. Impact of introducing a faecal immunochemical test (FIT) for haemoglobin into primary care on the outcome of patients with new bowel symptoms: a prospective cohort study
- Author
-
Rebecca McCann, Duncan Heather, Robert Steele, Christopher Hall, Craig Mowat, Callum G. Fraser, Jayne Digby, Francis A. Carey, and Judith A. Strachan
- Subjects
medicine.medical_specialty ,Colorectal Diseas ,Adenoma ,faecal haemoglobin ,Colorectal cancer ,colorectal cancer ,Disease ,Inflammatory bowel disease ,primary care ,Internal medicine ,medicine ,colorectal disease ,faecal biomarkers ,lcsh:RC799-869 ,Prospective cohort study ,business.industry ,Gastroenterology ,medicine.disease ,faecal immunochemical test ,digestive system diseases ,Test (assessment) ,Cancer registry ,lcsh:Diseases of the digestive system. Gastroenterology ,business ,bowel disease ,Record linkage - Abstract
ObjectiveTo determine whether a faecal immunochemical test (FIT) for faecal haemoglobin concentration (f-Hb) can be safely implemented in primary care as a rule-out test for significant bowel disease (SBD) (colorectal cancer (CRC), higher risk adenoma (HRA) and inflammatory bowel disease (IBD)) when used as an adjunct to the clinical assessment of new bowel symptoms.DesignSingle-centre prospective cohort study of all patients who attended primary care and submitted a FIT in the first calendar year of the service beginning December 2015. f-Hb was estimated using HM-JACKarc (Kyowa Medex) with a clinical cut-off of ≥10 µg Hb/g faeces. Incident cases of CRC were verified via anonymised record linkage to the Scottish Cancer Registry.Results5422 patients submitted 5660 FIT specimens, of which 5372 were analysed (positivity: 21.9%). 2848 patients were referred immediately to secondary care and three with f-Hb ConclusionIn primary care, measurement of f-Hb, in conjunction with clinical assessment, can safely and objectively determine a patient’s risk of SBD.
- Published
- 2019